Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. by Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik, Gun Anker, Bjørn Ostenstad, Steinar Lundgren, Terje Risberg, Ingvil Mjaaland, Gudbrand Skjønsberg, Turid Aas, Ellen Schlichting, Hans E Fjösne, Arne Nysted, Johan Richard Lillehaug, Per Eystein Lønning

Get full text